When was Evelo Biosciences founded?

Evelo Biosciences was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Evelo Biosciences located?

Evelo Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of Evelo Biosciences?

Simba Gill of Evelo Biosciences.

How many employees does Evelo Biosciences have?

As of Mar 01, 2026, the latest employee count at Evelo Biosciences is 50 - 199.

Is Evelo Biosciences a funded company?

Evelo Biosciences is a funded company, having raised a total of $167M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 04, 2015.

When was the latest funding round of Evelo Biosciences?

Evelo Biosciences' latest funding was a $***** Post IPO round on Jul 10, 2023, with participation from 1 investor.

Where does Evelo Biosciences rank among its competitors?

Evelo Biosciences ranks 616th amongst 2546 active competitors, of which 861 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Evelo Biosciences?

Evelo Biosciences' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Evelo Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.

Website: evelobio.com
Social
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Public

Total Funding

$167M in 4 rounds

Latest Funding Round

Post IPO, Jul 10, 2023, $*****

Investors

Google Ventures & 7 more

Ranked

616^th among 2546 active competitors

Employee Count

50 - 199 as on Mar 01, 2026

Investment & Acquisitions

Epiva Therapeutics

Similar Companies

Barinthus Biotherapeutics & 154 more

Exit Details

Public

View Evelo Biosciences' full profile

Evelo Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Evelo Biosciences, Inc. CIN: 465594527 , United States, Active	May 05, 2014	-	94 (As on Dec 31, 2022)	-

Evelo Biosciences got listed on May 11, 2018.

Click here to take a look at Evelo Biosciences's IPO in detail

Evelo Biosciences has raised a total funding of $167M over 4 rounds. Its first funding round was on Nov 04, 2015. Its latest funding round was a Post IPO round on Jul 10, 2023 for $*****. 1 investor participated in its latest round. Evelo Biosciences has 8 institutional investors.

Here is the list of recent funding rounds of Evelo Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 10, 2023	6833873	Post IPO	9709071	4493592	5417290	9744501
Mar 23, 2018	3728548	Series C	6398423	1840194	8749674	1661397
Jul 11, 2017	6204957	Series B	4935031	8807128	Flagship Pioneering & 4 more	1297854

Access funding benchmarks and valuations. Sign up today!

View details of Evelo Biosciences's funding rounds and investors

The founders of Evelo Biosciences is Brian Goodman. Simba Gill is the CEO of Evelo Biosciences.

Here are the details of Evelo Biosciences' key team members:

Brian Goodman: Former Co-Founder & Director of Evelo Biosciences and founder of 1 other company.
Simba Gill: CEO of Evelo Biosciences.

View details of Evelo Biosciences's Founder profiles and Board Members

Evelo Biosciences' employee count trend

Evelo Biosciences has 50 - 199 employees as of Mar 26. Here is Evelo Biosciences's employee count trend over the years:

Employee count trend for Evelo Biosciences

Uncover Evelo Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Evelo Biosciences include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Evelo Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
616th	Evelo Biosciences 2015, Cambridge (United States), Public	Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer	$167M	Celgene, Acks & 6 others	43/100